轻度缺血性中风和短暂缺血性发作后72小时内双重抗血小板治疗的影响:元分析
1School of Basic Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Brain injury
|November 18, 2025
概括
双重抗血小板治疗 (DAPT) 可以减少缺血性事件后的复发性中风. 阿司匹林加上二皮里达摩尔可能是一个更安全的替代品,但阿司匹林和提卡格勒勒的出血风险需要进一步调查.
科学领域:
- 神经学 神经学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缺血性中风 (IS) 和过渡性缺血性攻击 (TIA) 是致病率和死亡率的重要原因.
- 双抗血小板疗法 (DAPT) 越来越多地使用,但最佳方案和时间仍在研究中.
- 了解不同DAPT策略的比较疗效和安全性对于临床决策至关重要.
研究的目的:
- 评估在IS或TIA后72小时内开始的各种DAPT疗程的疗效和安全性.
- 使用网络元分析,将DAPT策略与单抗血小板治疗进行比较.
- 为了确定最佳的DAPT方案,以预防复发性中风,同时考虑出血风险.
主要方法:
- 进行了随机对照试验 (RCT) 的系统网络元分析.
- 数据来源于PubMed,Cochrane图书馆和ClinicalTrials.gov,截至2024年9月30日.
- 参与50,975名患者的12个RCT比较了六种治疗方案:阿司匹林,克洛皮多格雷尔,蒂卡格雷勒,阿司匹林+克洛皮多格雷尔,阿司匹林+蒂卡格雷勒和阿司匹林+迪皮里达摩尔.
主要成果:
- 与单独使用阿司匹林相比,用阿司匹林+克洛皮多格雷尔或阿司匹林+蒂卡格雷尔的DAPT显著减少了复发性中风.
- 阿司匹林+二皮里达摩尔在累计排名 (SUCRA) 下的表面值是最高的,这表明了有利的疗效与安全平衡.
- 虽然阿司匹林加提卡格勒罗尔增加了严重出血的几率,但置信区间非常宽,表明存在相当大的不确定性.
结论:
- 在预防复发性中风方面,DAPT比单独的阿司匹林更有效,特别是在症状出现后72小时内开始时.
- 由于估计不准确,与阿司匹林和蒂卡格勒罗尔联合治疗相关的出血风险是不确定的.
- 阿司匹林加上二皮里达摩尔可能是一个更安全,同样有效的替代品,强调需要个性化治疗策略.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Coronary Artery Disease V: Interprofessional Care
206
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
206
Peripheral Artery Disease III: Interprofessional Care
229
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
229
Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
Acute Coronary Syndrome IV: Interprofessional Care
203
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
203
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K


